Polio Outbreak in Pakistan
Pakistan continues to be dealing with a polio outbreak as four fresh cases have emerged, pushing the national tally to 37 this year, according to health officials on October 19, 2024. Health officials said that the regional reference laboratory for polio eradication at the National Institute of Health in Islamabad confirmed wild poliovirus type-1 (WPV1) in two children-one from each Balochistan and Khyber-Pakhtunkhwa.
In recent cases, a girl has been affected from Pishin, and two boys from Chaman and Noshki of Balochistan, and a girl from Lakki Marwat in KP. These are the first detections of the virus within Noshki and Lakki Marwat this year; isolated cases of poliovirus were previously reported within Chaman and Pishin. The province of Balochistan was the worst hit with 20 cases, Sindh had 10, Khyber Pakhtunkhwa had five, and Punjab and Islamabad had one case each.
A gigantic fight against polio has been on going in Pakistan- especially in Balochistan and southern KP-over the last two years. Immunisation campaigns have often been suspended or delayed because of local protests, insecurity, and community boycotts. Consequently, quite a number of children did not get the necessary vaccinations, making existing patches of vulnerability for the virus to flow within those pockets.
Noshki, located near Afghanistan's border, and Lakki Marwat have also recently reported some positive environmental samples that confirm the virus is present here, said a local reference laboratory official. Samples of latest cases are currently under genetic sequencing for checking spread of virus and origin.
As the threat of polio continues to grow, Pakistan has vowed to mount a nationwide campaign against it beginning from October 28. With the zeal to tackle the menace in the most effective manner, over 45 million children under the age of five will be vaccinated across the country.
Today, Afghanistan and Pakistan remain one of the few countries where polio has not yet been eradicated. The WHO said the virus remains a potential serious public health threat in areas with low vaccination coverage and weak surveillance.
The country declared itself polio-free since 2014 and has kept the disease on bay almost a decade with very robust vaccination programs; however, two cases of vaccine-derived poliovirus cases reported in recent days from Meghalaya create some amount of doubts over a possible resurgence. Experts observe that in India, despite these detections taking place, strong coverage of vaccination at 90-95% and mandatory surveillance measures keep the risk of this widespread outbreak at bay.
The experts point out, however, that such stable situation in India requires continued surveillance. "Countries like Pakistan and parts of Africa remain at a high risk because vaccination rates in those areas are much lower," Dr. Siddharth, public health expert, said. Vaccination is an indispensable act in order to avoid the spread of this incapacitating disease that manifests most importantly as a nervous system affliction leading to the paralysis of a long period.
With concerted efforts from health authorities, there is hope someday that the scourge of polio will be completely eradicated from the face of the earth and future generations will never suffer from its effects.
Credit: Instagram
V, a member of K-pop sensation BTS, has revealed that he has been dealing with hearing loss in one ear for about two and a half years.
V, whose real name is Kim Tae-hyung, opened up about the condition for the first time during a livestream amid the band's highly anticipated world tour.
"If the hearing in my left ear is at 100, it's only about 30 in my right," V said.
The 30-year-old singer said his hearing became worse while he was serving in the military. However, he initially ignored the problem, believing it was "a matter of mental strength," BBC reported.
He said he is now taking medication and visiting the hospital regularly.
V also admitted to pushing through pain during BTS' current tour, revealing that he is dangerously close to developing a stress fracture in his leg.
“My shin is right at the point just before a stress fracture. Even today on stage, my heart was set on running around, but it hurt too much at points and I couldn’t," he was quoted as saying by Channel News Asia.
Doctors have warned him about inflammation and early bone damage.
“It hasn’t reached a stress fracture yet, but there’s a lot of inflammation in my shin, and I think there’s some microdamage to the bone. I’ll be careful with myself so I can finish this tour properly,” he added.
BTS is currently halfway through its massive Arirang world tour, which will stop in Singapore in December and conclude in the Philippines in March 2027.
Hearing loss can happen when any part of the ear is not working in the usual way. This includes:
Hearing loss is a growing health concern worldwide. According to the WHO, more than 1.5 billion people—nearly 20% of the world's population—live with some degree of hearing loss. Of these, approximately 430 million people have disabling hearing loss requiring rehabilitation.
Hearing loss can have a significant impact on a person's life, affecting education and job prospects.
Hearing loss can occur at any time during life. Causes can range from genetic factors to conditions such as Down syndrome or Usher syndrome.
Other factors include:
To help prevent hearing loss in adults:
Credit: X.Com
Union Health Minister JP Nadda was admitted to AIIMS Delhi after experiencing uneasiness and underwent tests, including a coronary angiography. The hospital, in a statement, said he is stable and under observation in the cardiology department.
The 65-year-old minister was admitted on August 13 after experiencing uneasiness. He underwent tests, including coronary angiography.
“JP Nadda, Minister of Health and Family Welfare, was evaluated for uneasiness with tests including a coronary angiography on the evening of 13th August 2026. He is currently stable and admitted for observation in the Dept of Cardiology,” AIIMS said in a statement.
Heart problems do not always cause obvious symptoms. While common symptoms include chest pain or pressure, palpitations, and breathing difficulties, reduced blood flow to the heart can sometimes present with subtle signs or no symptoms.
Possible warning signs include:
Coronary angiography is a test used to check the blood vessels supplying the heart for narrowing or blockages.
A thin catheter is usually inserted through an artery in the wrist or groin. Contrast dye is injected, and X-rays are used to visualize the coronary arteries.
Doctors may recommend coronary angiography for:
Regular checkups can help detect heart disease early and monitor risk factors such as:
Regular monitoring can help detect changes early and support timely action to reduce long-term cardiovascular risk.
Regular heart checkups are particularly important for people who:
Depending on individual risk factors, a heart checkup may include:
Additional tests, such as CT coronary angiography or specialized cardiac biomarkers, may be recommended in some cases.
Credit: iStock
Sixty-two deaths in Australia have been reported to the medicines regulator, the Therapeutic Goods Administration (TGA), with suspected associations with GLP-1 medicines, including Ozempic, Wegovy and Mounjaro.
The TGA has also received reports of nearly 3,000 serious adverse events involving these medicines, which are used by hundreds of thousands of Australians, The Herald Sun reported.
Reported adverse reactions include nausea, pancreatitis, suicidal thoughts and a rare eye condition that can cause blindness.
Semaglutide, the active ingredient in Ozempic, used for type 2 diabetes, and Wegovy, approved for weight management, had the highest number of reported deaths with suspected associations.
Other medicines with reported suspected associations include Mounjaro (tirzepatide), Saxenda (liraglutide) and Trulicity (dulaglutide). These drugs are approved to treat type 2 diabetes, obesity, or both.
The reported deaths included:
The TGA states that adverse-event reports alone cannot determine how common a reaction is or be used to directly compare the safety of different medicines. The regulator also said the benefit-risk profile of these medicines remains positive when they are appropriately used for approved indications and in intended patients.
The TGA recently updated warnings for some GLP-1 medicines concerning non-arteritic anterior ischaemic optic neuropathy (NAION), a rare but serious eye condition.
Product warnings across the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class have been updated because of the potential association with the disorder.
NAION can cause permanent visual impairment, including blindness. The TGA notes that no treatment has been shown to improve visual acuity outcomes in people who develop the condition.
GLP-1 RA medicines are prescription drugs used primarily to manage type 2 diabetes and obesity. Thus, the TGA urged patients not to stop treatment on their own.
“These are prescription medicines, so people taking them should discuss benefits, risks and side effects with their healthcare professional rather than stopping or changing treatment based on headlines alone,” the TGA said.
The Australian reports come amid safety monitoring of GLP-1 medicines in other countries. At the same time, clinical evidence has shown important health benefits from some GLP-1 medicines, including reductions in cardiovascular risk and, in certain populations, overall mortality.
Data submitted to the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) showed 82 reported deaths associated with GLP-1 receptor agonists up to January 31, 2025. Of these, 22 were associated with use for weight loss and 60 with use for type 2 diabetes.
In the US, reports in the FDA's FAERS (FDA Adverse Event Reporting System) database have listed 162 deaths associated with Ozempic and Wegovy since 2018.
However, these figures should not be interpreted as confirmed deaths caused by the medicines. Adverse-event reporting systems record suspected associations and cannot by themselves establish a direct causal relationship. Millions of people use GLP-1 medicines, and reported cases can involve other health conditions or factors, including severe complications, dosing errors, and counterfeit or compounded products.
© 2024 Bennett, Coleman & Company Limited